You are viewing an archive version of the PSNC website taken on 18th April 2013. This site is not updated, and may be out of date or relate to old NHS structures.
For updated and current information, please visit our new website at
Skip Navigation
PSNC Home Page
Advanced Search

Pharmaceutical Services Negotiating Committee


The New Medicine Service (NMS) was the fourth Advanced Service to be added to the NHS community pharmacy contract; it commenced on 1st October 2011.

The service provides support for people with long-term conditions newly prescribed a medicine to help improve medicines adherence; it is initially focused on particular patient groups and conditions. The service was supported by a maximum investment of £55 million per annum in 2011/12 and 2012/13.

The NMS was implemented as a time-limited service commissioned until March 2013; it would continue beyond this time if all parties agreed that the service had provided demonstrable value to the NHS.

In March 2013 NHS England agreed to extend the service for a further six monthsThis means that community pharmacies can continue to recruit new patients to the service up until September 30th 2013 and will receive payment for these patients even where the service is completed in October or November 2013. The service specification remains the same and a maximum of £20 million in funding will be available for it during the six-month period.

No decision has been made about the future of the service beyond September 2013. This will be an NHS England decision that will take into account any emerging data from the Department of Health (DH) commissioned evaluation of the service. The evaluation is currently due to report in September, but the DH has said it may need to be extended to ensure that enough patients are recruited to it – the DH is considering this at the moment.

PSNC and NHS Employers envisaged that the successful implementation of NMS would:

  • improve patient adherence which will generally lead to better health outcomes
  • increase patient engagement with their condition and medicines, supporting patients in making decisions about their treatment and self-management
  • reduce medicines wastage
  • reduce hospital admissions due to adverse events from medicines
  • lead to increased Yellow Card reporting of adverse reactions to medicines by pharmacists and patients, thereby supporting improved pharmacovigilance
  • receive positive assessment from patients
  • improve the evidence base on the effectiveness of the service
  • support the development of outcome and/or quality measures for community pharmacy.

Directions, Guidance and Service Specification

The legal basis for the service is provided by the Secretary of State Directions. The service specification provides a 'plain English' version of the Directions and the official guidance from PSNC and NHS Employers provides essential information on the service for pharmacy contractors, their staff and PCTs.

The Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013

Service specification for the NMS

PSNC and NHS Employers guidance on the NMS for pharmacy contractors, their staff and PCTs

More information

1. Pharmacist knowledge and skills requirements / Learning materials

2. Notifying NHS England prior to providing the NMS / Funding and claiming payment

3. Medicines covered by the NMS

4. Providing the NMS / Patient consent / Info for patients / Interview schedule

5. Data requirements / NMS worksheet

6. Communicating with GPs and referring patients

7. Working with hospital colleagues

8. Service evaluation, NMS statistics and PharmOutcomes data

9. Other information on the NMS

10. Frequently Asked Questions (FAQs)

11. Further NMS resources


If pharmacy contractors and their staff have questions that are not answered by the above guidance, please contact